It may be diffficult to hold onto these gains in the medium term without additional news on trials, products, etc. Lang Walker may have deep pockets but he is not fronting a biotech vc.
The CR could provide some short term support assuming non-shareholders want a piece of the rights issues, or existing shareholders want more rights.
Ann: Neuren Completes Phase II trial Cohort 1 , page-10
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$16.77 |
Change
-0.530(3.06%) |
Mkt cap ! $2.126B | |||
| Open | High | Low | Value | Volume |
| $17.50 | $17.55 | $16.58 | $6.698M | 395.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 574 | $16.76 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.79 | 662 | 11 |
View Market Depth
| Last trade - 14.35pm 15/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |